Research News Archive - 2013

  • Researchers Identify Early Signs of Gastric Cancer
    December 20, 2013
    It has long been known that Helicobacter pylori infection can be a risk factor for gastric cancer, but what's not known is why the bug is harmless in some people but causes stomach tumors to form in others. An international team of researchers has identified a set of "glycans," or sugars attached to proteins, that they believe could help doctors identify the patients who are at most risk for developing gastric cancers. Scientists at the University of California at Davis, working with teams in Mexico and South Korea, showed significant differences in the glycan profiles of patients with gastric cancer and those with gastritis or ulcers, which they published in the journal Cancer Prevention Research. [Read more]
  • Scientists Define Three Subtypes of Gastric Cancer
    September 2013
    In the September issue of Gastroenterology, researchers from Centre for Computational Biology at Duke-National University of Singapore Graduate Medical School identified three classes of gastric cancer that have their own unique molecular profiles. The scientists studied 248 gastric tumors, then grouped them according to the genes they expressed. The three classifications-labeled "proliferative," "metabolic," and "mesenchymal"-showed different genetic mutations, as well as variations in their responses to commonly used therapies. The insights from this study may help clinicians tailor treatment regimens to patients, as well as guide the development of new drugs. [Read more]
  • Lilly Announces Second Positive Phase III Gastric Cancer Study
    September 26, 2013
    Great news from Eli Lilly's Phase III trial of ramucirumab in combination with paclitaxel in advanced gastric cancer. Improved overall survival and progression free survival ... [Read more]
  • Experimental Drug Offers Tailored Approach to Gastric Cancer
    July 22, 2013
    Over the summer, Cambridge, Mass.-based Merrimack Pharmaceuticals began enrolling patients in a trial of a new antibody-based drug called MM-111 for advanced gastric, esophageal and gastroesophageal junction (GEJ) cancers. What makes the research unique is that the drug is being tested in two subtypes of patients whose tumors possess the HER2 mutation, which has been proven in recent years to play prominently in some cases of gastric cancer. MM-111 will include some patients who are Her-2 positive but classified as ineligible to receive other Her-2-targetted therapies such as trastuzumab (Herceptin). The trial is taking place at 60 sites in the U.S. and abroad. [Read more]
  • Post-Surgery Chemo Boosts Survival
    July 4, 2013
    A study presented at the European Society For Medical Oncology conference in July showed a 34 percent reduction in mortality risk for patients who received eight cycles of chemotherapy after surgery. The patients in the trial were given a combination of capecitabine and oxaliplatin (XELOX) after undergoing D2 gastrectomies, then compared to patients who had surgery alone. The trial was performed in China, South Korea, and Taiwan, and the primary endpoint was three years of disease-free survival. [Read more]
  • GSK's breast cancer drug Tykerb fails in gastric cancer study
    June 3, 2013
    GlaxoSmithKline announced that unfortunately, its breast cancer drug Tykerb (lapatinib) in combination with chemotherapy did not improve survival rates for patients with gastric cancer compared to the use of chemotherapy alone. Lapatinib, which is ... [Read more]
  • ASLAN's Pan-HER Inhibitor Shows Positive Data In Gastric Cancer PhII Study
    June 3, 2013
    In Asia, a Phase II study conducted at Seoul National University Hospital, South Korea showed positive data in heavily pretreated people with recurrent/metastatic gastric carcinoma whose tumors were HER2 amplified or coexpressing EGFR and HER2 ... [Read more]
  • Removal of nodes does not aid survival in gastric cancer
    June 5, 2013
    Researchers at Leiden University Medical Center, The Netherlands, have clarified the role of lymph node dissection in gastric cancer by comparing two groups of patients. They received either limited lymph node dissection (the D1 procedure) or more extensive lymph node dissection (D2). There was no difference in long term survival between the two groups ... [Read more]
  • Gastric Cancer with Epstein-Barr Virus Is Less Deadly
    May 31, 2013
    A small but significant percentage (9%) of gastric cancers contain Epstein-Barr virus (EBV). Findings from a large study published in Journal Watch Gastroenterology, support previous data showing a better prognosis for gastric cancers that contain Epstein-Barr virus ... [Read more]
  • mmunotherapy is not just for melanoma anymore
    May 31, 2013
    A new class of drugs are showing to be effective in clinical trials – immunotherapies. They were high on the list of results to watch at ASCO this year. Pharmaceutical companies are developing clinical trials for these therapies across tumor type – from lung to gastric, there are high hopes... [Read more]
  • Does salt contribute to gastric cancer? Questions arise…
    May 14, 2013
    Who to believe? Recently researchers are starting to question the role salt has in gastric cancer... [Read more]
  • Breath Test for Stomach Cancer
    March 8, 2013
    A new method for diagnosing gastric cancer via breath samples can help distinguish between cancer and other gastric ailments such as ulcers as much as 90 percent of the time, according to BBC News. The 130-person study was published this week (March 5) in the British Journal of Cancer. [Read more]
  • Bayer wins new use for fast-moving cancer drug Stivarga
    Feb. 26, 2013
    Bayer's new cancer drug Stivarga has already added a notch to its belt. Cleared by the FDA last year to treat colorectal cancer, the drug is now approved as a treatment for a rare form of gastric cancer, gastrointestinal stromal tumors... [Read more]
  • Racial gap in gastric cancer survival narrows at 3 years
    February 14, 2013
    Race is a significant predictor of the odds of surviving gastric cancer at the time of diagnosis: Its impact lessens the longer the patient survives, an analysis of data on 24,657 patients who underwent potentially curative surgery suggests... [Read more]
  • Treatment Advances Reported for Gastrointestinal Cancers
    January 22, 2013
    Prior to the 10th annual Gastrointestinal Cancers Symposium, being held January 24-26, 2013 in San Francisco, CA, a January 22 press cast featured studies related to... [Read more]